Damora Therapeutics (DMRA) Shares Outstanding (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Shares Outstanding data on file, last reported at $60.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 4460.28% year-over-year to $60.3 million; the trailing twelve-month figure through Mar 2026 stood at $60.3 million (up 4460.28% YoY), and the FY2025 full-year result was $16366.0, down 98.76% from the prior year.
• Shares Outstanding for Q1 2026 stood at $60.3 million, up from $16366.0 in the prior quarter.
• Across five years, Shares Outstanding topped out at $60.3 million in Q1 2026 and bottomed at $1.0 million in Q4 2022.
• The 5-year median for Shares Outstanding is $1.3 million (2025), against an average of $10.4 million.
• The widest annual swing landed in 2025, when Shares Outstanding tumbled 98.76%; it then soared 4460.28% in 2026.
• A 5-year view of Shares Outstanding shows it stood at $1.0 million in 2022, then gained by 5.69% to $1.1 million in 2023, then advanced by 21.44% to $1.3 million in 2024, then sank by 98.76% to $16366.0 in 2025, then surged by 368366.41% to $60.3 million in 2026.
• The last three Shares Outstanding figures came in at $60.3 million (Q1 2026), $16366.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison